URGENT RECALL: BRAVELLE® FOLLICLE-STIMULATING HORMONE RECALLED FOR LACK OF EFFICACY
In October of 2015, Ferring Pharmaceuticals quietly initiated a voluntary, class 2 recall of Bravelle® (75 IU dose, injection-method, NDC 55566850506), for reasons of sub-potency. In other words, it did not contain the right amount of active ingredient.
The recall applies to Bravelle® products sold between March 27, 2014 and October 6, 2015. If you or a loved one experienced any of the following losses or injuries you may be entitled to compensation:
- You spent thousands of dollars on the ineffective Bravelle®.
- You spent tens of thousands of dollars on fertility procedures (such as in vitro fertilization or IVF) that were ineffective because Bravelle® did not help you adequately make or release eggs.
- You experienced undue physical pain and suffering and side effects from Bravelle®.
- You experienced other injuries from your use of Bravelle® such as failed pregnancies and fertilizations.
- You experienced other related emotional damages as a result of your use of Bravelle®.
- Loss of your opportunity to have any children because Bravelle® wasted valuable time.
Affected lots were distributed between March 27, 2014, and October 6, 2015.
In some cases Ferring Pharmaceuticals has offered to pay victims the purchase price of Bravelle®. Don’t sacrifice your right to a full recovery for all of your damages just because you want a quick payment. You need a lawyer to get you full compensation.
CALL THE PRODUCT LIABILITY ATTORNEYS AT ANDREWS & THORNTON FOR A FREE CONSULTATION BEFORE YOU ACCEPT ANY PAYMENT OR YOU COULD BE WAIVING YOUR RIGHTS.
Toll Free: (800) 664-1734
Email us at info@andrewsthornton.com
visit us at www.andrewsthornton.com
© 2015 Andrews & Thornton, LLC. All Rights Reserved
